Juvenile dermatomyositis: common manifestations of a rare disease
DOI:
https://doi.org/10.25753/BirthGrowthMJ.v29.i3.14261Keywords:
exanthema, juvenile dermatomyositis, myositisAbstract
Juvenile dermatomyositis is an autoimmune systemic vasculopathy, mainly characterized by chronic inflammation of the striated muscle and skin. The authors report the case of a 15-year-old boy presenting with a four-month history of myalgia and proximal muscle weakness on the upper and lower limbs. These symptoms were associated with heliotrope palpebral exanthema, erythema in the dorsum of the hands, Gottron’s papules, erythematous and petechial rash on the extensor face of the thighs, and mild dysphagia for solids. Blood tests revealed an increase in muscle enzymes and electromyography showed changes suggestive of severe acute myopathy. Intravenous methylprednisolone was initiated, followed by a combination regimen of prednisolone and methotrexate. Progressive dysphagia, cutaneous abnormality, and muscular strength improvement were noted. With this case, the authors intend to raise awareness of a rare disease with an essentially clinical diagnosis, presenting in most cases with characteristic manifestations that should be recognised.
Downloads
References
Rider GL, Katz JD, Jones OU. Developments in the Classification and Treatment of the Juvenile Idiopathic Inflammatory Myopathies. Rheum Dis Clin North Am. 2013; 39:877-904.
Prevalence and incidence of rare diseases: Bibliographic data. Orphanet Report Series. Rare Diseases Collection. January 2018.
Rider GL, Lindsley CB, Miller FW. Juvenile Dermatomyosites. Textbook of Pediatric Rheumatology. Chapter 26, p. 351-83. Elsevier, Seventh edition.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292:344-7.
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292:403-7.
Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. European League Against Rheumatism/American College of Rheumatology Arthritis Rheumatol. 2017; 69:227182.
Enders FB, Bader- Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman MF, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 2017; 76:329–40.
Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Paediatric Rheumatology International Trials
Organisation (PRINTO). Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 2016; 13;387:671-8.
Inocencio J, Enríquez-Merayo E, Casado R, González-Granado LI. Subcutaneous Immunoglobulin in Refractory Juvenile Dermatomyositis. Pediatrics. 2016; 137. pii: e20153537.
Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford). 2016; 2.pii: kew146.
Moghadam-Kia, Oddis CV, Aggarwal R. Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics. Clin Rev Allergy Immunol. 2017; 52:81-7.
Chojnowski MM, Felis-Giemza A, Olesińska M. Capillaroscopy – a role in modern rheumatology. Reumatologia 2016; 54:67–72.
Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009; 48:607-12.
Holden DJ, Brownell AKW, Fritzler MJ. Clinical and serological features of patients with polymyositis or dermatomyositis. Can Med Assoc J. 1985; 132:649–53.
Carbonell MS, Antoli HC, Fonseca AL, Talayero JM, Tomás PE. Dermatomyositis. Presentation of a mild to moderate case with early dysphagia. An Pediatr (Barc) 2015; 82:e86-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 NASCER E CRESCER - BIRTH AND GROWTH MEDICAL JOURNAL
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in the Birth and Growth Medical Journal are Open Access and meet the requirements of funding agencies and academic institutions. Third-party use of published content is permitted under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) license. It is the responsibility of authors to obtain permission for reproducing figures, tables, or other materials from previously published works.
Authors must submit a Conflict of Interest statement and an Authorship Form together with their manuscript. A confirmation email will be sent to the corresponding author upon receipt of the submission. Authors are also permitted to deposit their articles in institutional or personal repositories, provided that the original publication in the Birth and Growth Medical Journal is clearly indicated and the terms of the Creative Commons license are respected.
